Mixed bag for sure.
DLT which limits the dose increase, but the positive is cumulatively the dosage is still the same ie 8x6 vs 12v4.
another CR, albeit at 2 X 12.
going into pretaxane is great, as it allows the potential for P3 to be earlier stage cohorts. This will mean a larger piece of the pie when things eventuate(a long road ahead, but important for potential suitors to determine revenue).
pretaxane 46% over 80% reduction in PSA, with 30% dosed at 4-8GBq and the remaining dosed at 12-24GBq. Hopefully when this is dosed at RP2D(48GBq), we will see better responses.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.13 |
Change
0.120(5.97%) |
Mkt cap ! $684.4M | |||
| Open | High | Low | Value | Volume |
| $2.09 | $2.16 | $2.04 | $4.243M | 2.013M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2553 | $2.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.14 | 4455 | 3 |
View Market Depth
| Last trade - 16.20pm 24/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |